triple agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
与仅é¶å‘å•ä¸€å—体的åŒç±»è¯ç‰©ç›¸æ¯”，瑞他é²è‚½å¢žåŠ èƒ°é«˜è¡€ç³–ç´ å—体æˆåˆ†ï¼Œç†è®ºä¸Šå¯æ高能é‡æ¶ˆè€—并改å˜è„‚肪分布。临床ä¸è§‚察到的体é‡å˜åŒ–是å¦ä¸»è¦æ¥è‡ªè¯¥é¢å¤–机制，目å‰å°šæ— å®šè®ºã€‚èƒƒè‚ é“å应是该类è¯ç‰©å¸¸è§ä¸è‰¯äº‹ä»¶ï¼Œè¯•éªŒä¸é€šè¿‡å‰‚é‡é€’增和监测进行管ç†ã€‚åœè¯åŽä½“é‡åå¼¹ã€ä¸ªä½“差异和长期è€å—性ä»éœ€æ›´å¤šæ•°æ®ã€‚
ç‘žä»–é²è‚½æ˜¯ä¸€ç§åœ¨ç ”åˆæˆè‚½ï¼ŒåŒæ—¶ä½œç”¨äºŽèƒ°é«˜è¡€ç³–ç´ æ ·è‚½-1ã€è‘¡è„ç³–ä¾èµ–æ€§ä¿ƒèƒ°å²›ç´ å¤šè‚½å’Œèƒ°é«˜è¡€ç³–ç´ å—体。该分å属于多å—体激动剂类别，尚未获得任何监管机构的上市批准。当å‰ä¸´åºŠå¼€å‘主è¦é’ˆå¯¹è‚¥èƒ–å’Œ2åž‹ç³–å°¿ç—…ï¼Œç ”ç©¶ä»£å·ä¸ºLY3437943。已确立的信æ¯åŒ…括å—体é¶ç‚¹å’Œéƒ¨åˆ†ä¸æœŸè¯•éªŒç»“果；最终疗效ã€é•¿æœŸå®‰å…¨æ€§å’Œé€‚用人群ä»å±žå¼€æ”¾é—®é¢˜ã€‚
å¼€å‘进程从早期å•æ¬¡å’Œå¤šæ¬¡ç»™è¯ç ”究推进至大规模åŽæœŸè¯•éªŒã€‚公开报告显示，å‚与者在体é‡å’Œç›¸å…³ä»£è°¢æŒ‡æ ‡ä¸Šå‡ºçŽ°å˜åŒ–，但完整数æ®éœ€ç»åŒè¡Œè¯„审并接å—独立å¤æ ¸ã€‚试验设计通常包括éšæœºã€åŒç›²å’Œå¯¹ç…§è®¾ç½®ï¼Œä»¥åŒºåˆ†è¯ç‰©æ•ˆåº”与行为干预。监管æäº¤å’Œæ ‡ç¾èŒƒå›´å°šæœªç¡®å®šï¼›é•¿æœŸç»´æŒæ•ˆæžœä¸Žå¿ƒè¡€ç®¡ç»“å±€ä»æ˜¯å¼€æ”¾é—®é¢˜ã€‚
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| ç ”ç©¶ä»£å· | LY3437943 | 文献ä¸å¸¸ç”¨çš„å®žéªŒæ ‡è¯† |
| è¯ç‰©ç±»åˆ« | 三é‡å—体激动剂 | é¶å‘GLP-1ã€GIPä¸Žèƒ°é«˜è¡€ç³–ç´ å—体 |
| å¼€å‘çŠ¶æ€ | åŽæœŸä¸´åºŠç ”究 | 尚未获批上市 |
| 主è¦ç ”究人群 | 肥胖与2åž‹ç³–å°¿ç—… | 入组æ¡ä»¶ä¾è¯•éªŒæ–¹æ¡ˆè€Œå®š |
| 常è§åŒä¹‰è¯ | ç‘žä»–é²è‚½ï¼›LY3437943 | å称拼写å¯èƒ½å› è¯è¨€å’Œå‡ºç‰ˆç‰©è€Œå¼‚ |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
=== Technical issues during the flight === On the 19th orbit, the first sign of trouble appeared when the spacecraft 0.05 g (0.5 m/s2) light came on. However, this turned out to be a faulty indicator, and the spacecraft was not reentering. On the 20th orbit, Cooper lost all attitude readings. The 21st orbit saw a short-circuit occur in the bus bar serving the 250 VA (115 V, 400 Hz) main inverter. This left the automatic stabilization and control system without electric power. On the 21st orbit, John Glenn on board the tracking ship Coastal Sentry Quebec near Kyushu, Japan, helped Cooper prepare a revised checklist for retrofire. Due to the system malfunctions, many of the steps would have to be done manually. Only Hawaii and Zanzibar were in radio range on this last orbit, but communications were good. Cooper noted that the carbon dioxide level was rising in the cabin and in his spacesuit. He told Carpenter as he passed over Zanzibar, "Things are beginning to stack up a little." Throughout the problems, Cooper remained cool, calm and collected. Cooper did not experience much of an appetite during the flight and ate only because it was scheduled. The food containers and water dispenser system proved unwieldy and he was not able to properly prepare freeze-dried food packages, so he limited his consumption to cubed food and bite-sized sandwiches. Cooper found the cubed food largely unpalatable, which contributed to his lack of eating.
At the second trial, the defence called eight medical experts, all university professors, who testified that Sunny's two comas had not been caused by insulin, but by a combination of ingested (not injected) drugs, alcohol, and chronic health conditions. The experts were John Caronna (chairman of neurology, Cornell); Leo Dal Cortivo (former president, U.S. Toxicology Association); Ralph DeFronzo (medicine, Yale University); Kurt Dubowski (forensic pathology, University of Oklahoma); Daniel Foster (medicine, University of Texas Southwestern); Daniel Furst (medicine, University of Iowa); Harold Lebovitz (director of clinical research, State University of New York); Vincent Marks (clinical biochemistry, Surrey, vice-president Royal College of Pathologists and president, Association of Clinical Biochemistry); and Arthur Rubinstein (medicine, University of Chicago). Cortivo testified that the hypodermic needle tainted with insulin on the outside (but not inside) would have been dipped in insulin but not injected; injecting it through flesh would have wiped it clean. Evidence also showed that Sunny's hospital admission three weeks before her final coma showed she had ingested at least 73 aspirin tablets, a quantity that could only have been self-administered, and which indicated her state of mind. Dershowitz, in his book Taking the Stand, writes about von Bülow's dinner party after he was found not guilty at his trial.
== AFL career == Fletcher was recruited by the Essendon Football Club in the 1992 National Draft. He played his first senior game against Carlton in his senior year of high school at Penleigh and Essendon Grammar School. Right from the get-go, Fletcher proved to be a highly impactful player. At 18 years old, he won a Longest Kick competition, a highly desirable trait that would serve him well for the next 22 years. He was a key member of the 1993 premiership team in his first AFL season, a team which is often referred to as the "Baby Bombers". Fletcher also played in the 2000 premiership team, a year in which he also won the Crichton Medal as Essendon's best and fairest and was selected in the All-Australian team.
=== Compound mixtures in Polymyxin B drug === In formulations for the commercial pharmaceutical Polymyxin drug, the principal Polymyxins are B1 and B2, amounting to 75% and 15% of the final mixture, respectively. Polymyxin B1, in turn, comprises several isomers, like isoleucine-polymyxin B1 and B1-1. The major impediment in the purification and isolation of one isomer is due to the minimal structural differences between Polymyxin B1 and B2, differing only in one carbon at the 6th position of the fatty acyl side chain linked to the D-Phenylalanine of the structure. Polymyxin B1 contains 6-methyl octanoic acid, while Polymyxin B2 contains 6-methyl heptanoic acid. Similarly, Polymyxins B3 and B4 also differ at this position, with B3 containing octanoic acid and B4 featuring heptanoic acid.
Sources: en.wikipedia.org
Originally launched in February 2008, the SBKB is a free resource that provides information on protein sequence and keyword searching, as well as modules describing target selection, experimental protocols, structure models, functional annotation, metrics on overall progress, and updates on structure determination technology. Like the PDB, it is directed by Dr. Helen M. Berman and hosted at Rutgers University. The PSI Materials Repository, established in 2006 at the Harvard Institute of Proteomics, stores and ships PSI-generated plasmid clones. Clones are sequence-verified, annotated and stored in the DNASU Plasmid Repository, currently located at the Biodesign Institute at Arizona State University. As of September 2011, there are over 50,000 PSI-generated plasmid clones and empty vectors available for request through DNASU in addition to over 147,000 clones generated from non-PSI sources. Plasmids are distributed to researchers worldwide. Now called the PSI:Biology Materials Repository, this resource has a five-year budget of $5.4 million and is under the direction of Dr. Joshua LaBaer, who moved to Arizona State University in the middle of 2009, taking the PSI:Biology-MR with him.
The carnitine shuttle is a biochemical reaction used to transport long chain fatty acids (LCFAs) from the cytosol into the matrix of the mitochondria so that they may be metabolized. While some fatty acids can, long chain fatty acids cannot pass through the mitochondrial membrane. However, carnitine (specifically its stereoisomer l-carnitine) can. The shuttle utilizes this to its advantage by attaching the LCFAs to carnitine. This new acyl-carnitine can pass through the membrane, after which it is split, with the newly separated carnitine being sent back out to shuttle more LCFAs, and the newly separated LCFAs undergoing beta oxidation to release their energy. The carnitine shuttle is an example of an antiporter system, and is a part of the broader class of metabolic reactions that constitute lipid metabolism. It is a highly conserved system found primarily in animals/some eukaryotes, although bacteria and plants still use carnitine for other things such as being an osmoprotectant, or being and electron acceptor in the electron transport chain. The shuttle system is implicated in many metabolic disorders, in the form of deficiencies of the enzymes in the system.
However, production climbed markedly when another cigarette-making machine was developed in the 1880s by James Albert Bonsack, which vastly increased the productivity of cigarette companies, which went from making about 40,000 hand-rolled cigarettes daily to around 4 million. At the time, these imported cigarettes from the United States had significant sales among British smokers. In the English-speaking world, the use of tobacco in cigarette form became increasingly widespread during and after the Crimean War, when British soldiers began emulating their Ottoman Turkish comrades and Russian enemies, who had begun rolling and smoking tobacco in strips of old newspaper for lack of proper cigar-rolling leaf. This was helped by the development of tobaccos suitable for cigarette use, and by the development of the Egyptian cigarette export industry.
Of the various methods of labeling biomolecules, fluorescent labels are advantageous in that they are highly sensitive even at low concentration and non-destructive to the target molecule folding and function. Green fluorescent protein is a naturally occurring fluorescent protein from the jellyfish Aequorea victoria that is widely used to tag proteins of interest. GFP emits a photon in the green region of the light spectrum when excited by the absorption of light. The chromophore consists of an oxidized tripeptide -Ser^65-Tyr^66-Gly^67 located within a β barrel. GFP catalyzes the oxidation and only requires molecular oxygen. GFP has been modified by changing the wavelength of light absorbed to include other colors of fluorescence. YFP or yellow fluorescent protein, BFP or blue fluorescent protein, and CFP or cyan fluorescent protein are examples of GFP variants. These variants are produced by the genetic engineering of the GFP gene. Synthetic fluorescent probes can also be used as fluorescent labels. Advantages of these labels include a smaller size with more variety in color. They can be used to tag proteins of interest more selectively by various methods including chemical recognition-based labeling, such as utilizing metal-chelating peptide tags, and biological recognition-based labeling utilizing enzymatic reactions. However, despite their wide array of excitation and emission wavelengths as well as better stability, synthetic probes tend to be toxic to the cell and so are not generally used in cell imaging studies.
The author of a 1994 study concluded that it was only in the second half of the 20th century that medical advances have extended the life expectancy of those who live into adulthood. though this is flatly contradicted by 19th- and early 20th-century census and registration data and by estimates for medieval and ancient populations: US and English expectation of remaining years at age 15 for example rose from about 44 in the mid-19th century to 56 by 1950, and has since increased to 65–67; for English landholders (a relatively privileged group) it was 33 years c.1300, while Ulpian's life table for ancient Rome indicates only 30 years. Reliable references to individuals in antiquity who lived past 100 years are quite rare, but they do exist. For instance, Cicero's wife Terentia was reported by Pliny the Elder to have lived from 98 BC to 6 AD, 103 years. Regnal dates of Bronze Age monarchs are notoriously unreliable; the sixth dynasty Egyptian ruler Pepi II is sometimes listed as having lived c. 2278 – c. 2184 BC, as he is said to have reigned for 94 years, but alternative readings cite a reign of just 64 years. Adad-guppi, mother of the last king of the Neo-Babylonian Empire Nabonidus apparently lived from c. 648-544 BC (c. 104 years) according to inscriptions on funeral steles. Zhao Tuo, a Qin Dynasty general, reportedly lived to age 103. Tuoba Liwei also reportedly lived to 103. Marcus Valerius Corvus reportedly lived to 100. Diogenes Laërtius (c.
Sources: en.wikipedia.org
== Treatment == There are many causes of necrosis, and as such treatment is based upon how the necrosis came about. Treatment of necrosis typically involves two distinct processes: Usually, the underlying cause of the necrosis must be treated before the dead tissue itself can be dealt with.
One test is for antibodies against the acetylcholine receptor; the test has a reasonable sensitivity of 80–96%, but in ocular myasthenia, the sensitivity falls to 50%. A proportion of the people without antibodies against the acetylcholine receptor have antibodies against the MuSK protein. Less than 1% of patients with myasthenia gravis have antibodies against low-density lipoprotein receptor-related protein 4 (i.e., LRP4). In suspicious situations, testing can be performed for the similar symptomatic Lambert-Eaton syndrome.
1993/950) Banking Act 1987 (Exempt Persons) Order 1993 (S.I. 1993/953) Financial Services Act 1986 (Overseas Investment Exchanges and Overseas Clearing Houses) (Periodical Fees) Regulations 1993 (S.I. 1993/954) City of Glasgow and Monklands Districts (Bargeddie) Boundaries Amendment (No. 2) Order 1993 (S.I. 1993/960) Child Support Appeals (Jurisdiction of Courts) Order 1993 (S.I. 1993/961) Education (School Teachers' Pay and Conditions) Order 1993 (S.I. 1993/962) Social Security Benefits (Miscellaneous Amendments) (No. 2) Regulations 1993 (S.I. 1993/963) National Assistance (Assessment of Resources) (Amendment) Regulations 1993 (S.I. 1993/964) Child Benefit and Social Security (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/965) Child Support Act 1991 (Commencement No. 3 and Transitional Provisions) Amendment Order 1993 (S.I. 1993/966) Gaming Act (Variation of Monetary Limits) Order 1993 (S.I. 1993/967) Gaming Clubs (Hours and Charges) (Amendment) Regulations 1993 (S.I. 1993/968) Legal Aid (Scotland) Act 1986 Amendment Regulations 1993 (S.I. 1993/969) Civil Legal Aid (Financial Conditions and Contributions) (Scotland) Regulations 1993 (S.I. 1993/970) Advice and Assistance (Financial Conditions) (Scotland) Regulations 1993 (S.I. 1993/971) Advice and Assistance (Assistance by Way of Representation) (Scotland) Amendment Regulations 1993 (S.I. 1993/972) Advice and Assistance (Scotland) (Prospective Cost) Amendment Regulations 1993 (S.I. 1993/973) Education (Grants for Further Training of Teachers and Educational Psychologists Etc.) (Scotland) Regulations 1993 (S.I.
== Uniformity == The chemical processing and synthesis of high performance technological components for the private, industrial and military sectors requires the use of high purity ceramics, polymera, glass-ceramics, and composite materials. In condensed bodies formed from fine powders, the irregular sizes and shapes of nanoparticles in a typical powder often lead to non-uniform packing morphologies that result in packing density variations in the powder compact. Uncontrolled agglomeration of powders due to attractive van der Waals forces can also give rise to in microstructural inhomogeneities. Differential stresses that develop as a result of non-uniform drying shrinkage are directly related to the rate at which the solvent can be removed, and thus highly dependent upon the distribution of porosity. Such stresses have been associated with a plastic-to-brittle transition in consolidated bodies, and can yield to crack propagation in the unfired body if not relieved. In addition, any fluctuations in packing density in the compact as it is prepared for the kiln are often amplified during the sintering process, yielding inhomogeneous densification. Some pores and other structural defects associated with density variations have been shown to play a detrimental role in the sintering process by growing and thus limiting end-point densities. Differential stresses arising from inhomogeneous densification have also been shown to result in the propagation of internal cracks, thus becoming the strength-controlling flaws.
Sources: en.wikipedia.org
尚未。它ä»å¤„äºŽä¸´åºŠç ”ç©¶é˜¶æ®µï¼Œä»»ä½•ç›‘ç®¡æ‰¹å‡†éƒ½å–决于æ£åœ¨è¿›è¡Œçš„试验结果和æ交审评。å¯å…¬å¼€èŽ·å–çš„ä¿¡æ¯ä»¥è¯•éªŒæ³¨å†Œå’Œä¼šè®®æ‘˜è¦ä¸ºä¸»ã€‚
å¸ç¾Žæ ¼é²è‚½ä¸»è¦é¶å‘GLP-1å—体，而瑞他é²è‚½åŒæ—¶ä½œç”¨äºŽGLP-1ã€GIPå’Œèƒ°é«˜è¡€ç³–ç´ å—体。这ç§ä¸‰é‡æœºåˆ¶æ—¨åœ¨äº§ç”Ÿä¸åŒçš„代谢效应，但临床差异ä»éœ€å¤´å¯¹å¤´ç ”究确认。
长期心血管结局ã€åœè¯åŽç»´æŒæ•ˆæžœã€ç½•è§ä¸è‰¯äº‹ä»¶å’Œä¸åŒäººç¾¤ä¸çš„获益风险比尚未完全确定。完整三期数æ®å’Œç›‘管审评将影å“结论。
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.